Silence Therapeutics PLC Silence to present at Cowen Health Care Conference (5989G)
March 05 2018 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 5989G
Silence Therapeutics PLC
05 March 2018
Silence Therapeutics to Present at the Cowen 38th Annual Health
Care Conference
London, 5(th) March 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that Ali Mortazavi, Chief Executive
Officer, will present at the Cowen 38th Annual Health Care
Conference on Tuesday, 13 March, 2018 at 10:30am EDT in Boston,
MA.
The presentation will be webcast live and may be accessed by
visiting Silence's website at
http://www.silence-therapeutics.com/investors/. A replay of the
webcast will be available for 14 business days.
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Ali Mortazavi, Chief Executive 6900
Officer
David Ellam, Chief Financial
Officer
Peel Hunt LLP (Nominated Tel: +44 (0)20 7418
Adviser and Broker) 8900
James Steel/Oliver Jackson
Media Enquiries:
Optimum Strategic Communications Tel: +44 (0) 20 3714
Mary Clark/ Eva Haas/Hollie 1788
Vile
silence@optimumcomms.com
IR Enquires - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCJTMFTMBIMBIP
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2023 to Apr 2024